Biotechnology Can Address the Mystery and Urgency of Alzheimer’s Disease

Authors

  • Mina Marmor Sectoral Asset Management
  • Henry I Miller

DOI:

https://doi.org/10.5912/jcb826

Keywords:

alzheimer's disease, finance

Abstract

Alzheimer’s disease (AD), a scourge that in time could virtually bankrupt healthcare systems worldwide, is one of the most intensively researched areas of medicine. Because of the existing uncertainty about its pathophysiology the unavailablity of reliable diagnostic tests, it is difficult to predict which prophylactic or therapeutic interventions are likely to be effective, but many biotechnology-derived drugs are prime candidates.  We summarize the most promising approaches and drugs.

Published

2018-02-01

Issue

Section

Commentary